Edition:
United States

ReNeuron Group PLC (RQE.L)

RQE.L on London Stock Exchange

1.98GBp
--
Change (% chg)

0.00 (+0.00%)
Prev Close
1.98
Open
2.05
Day's High
--
Day's Low
--
Volume
2,225,146
Avg. Vol
1,890,689
52-wk High
2.95
52-wk Low
1.55

Chart for

About

ReNeuron Group plc is a clinical-stage company. The Company, through its subsidiaries, is engaged in researching and developing cell-based therapies. The Company's products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells... (more)

Overall

Beta: 0.82
Market Cap(Mil.): £64.08
Shares Outstanding(Mil.): 3,164.62
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 196.13 16.04
EPS (TTM): -- -- --
ROI: -- -11.69 35.70
ROE: -- -36.44 15.40

BRIEF-FDA approves Reneuron's cryopreserved formulation of retinal stem cell therapy candidate​

* ‍FDA approves cryopreserved formulation of reneuron's retinal stem cell therapy candidate​ Source text for Eikon: Further company coverage: (Reporting By London Bureau)

Jun 19 2017

Earnings vs. Estimates